Many clinical trials of molecular target drugs have been done against advanced lung cancer, however, majority did not meet the primary endpoint. Positive studies of EGFR-TKI such as BR21 and Interest used unselected populations of non-small cell lung cancer. It was quite difficult to explain why they were positive. In the present review, the difficulties of clinical trial design in molecular target drugs were discussed based on the differences of the magnitude of antitumor activity and the target tumor cell population between cytotoxic drugs and molecular target therapy. (J Lung Cancer 2008;7(1):1 8)
The therapeutic efficacy of cytocidal anticancer drugs for lung cancer has reached a plateau(1∼4), and it is extremely agents, but only negative data have been obtained (Table 1) .
EGFR-TKIs
EGFR-TKIs are molecularly targeted drugs that selectively modify molecular biological abnormalities of tumor cells themselves(9∼12). The amazing antitumor effect of EGFRTKIs in cases in which platinum-taxane therapy failed attracted interest(13∼16), but it was difficult to demonstrate that they contributed to any survival benefit(17∼20). Erlotinib is used as second-line and third-line chemotherapy in cases of platinum- taxane failure, and it has shown a survival benefit in comparison with placebo in unselected non-small cell cancer (21) .
By contrast, it was impossible to show any overall survival benefit of gefitinib in a group of similar cases that were almost the same although the results were marginal (22, 23) , and while significant prolongation of survival time was observed in Asians (no Japanese were included) by post-study stratification, no difference in survival time at all from the placebo control group was observed in Caucasians. Moreover, four trials of standard chemotherapy (carboplatin+paclitaxel, gemcitabine+cisplatin)
±EGFR-TKI all yielded negative data(17∼20), and in a comparative study with gefitinib as intensification chemotherapy for stage III non-small cell cancer the survival time of the gefitinib group was instead significantly poorer than in the control group (24) . Adjuvant studies using EGFR-TKIs in resected cases was started in Japan and North America but case entry was poor, and it was stopped before completion (25) .
Two comparative studies of docetaxel versus the EGFR-TKI gefitinib in cases in which platinum-taxane was ineffective yielded different results. Even though the response rate to gefitinib by the Japanese patients was higher than in the Western population, it was impossible to demonstrate noninferiority versus docetaxel in the V15-32 study conducted in Japan (26) . By contrast, non-inferiority was demonstrated in the Interest study conducted in a large number of cases in Western countries (27) .
The majority of the results of these studies were not what the investigators expected (Table 2) , and numerous questions have arisen.
1) In placebo-controlled studies in cases in which platinumtaxane therapy was ineffective, the ISEL study (gefitinib) was negative (22) , whereas BR-21 (erlotinib) was positive (21) . The efficacy of gefitinib was marginal, but no difference at all was observed in the Western subjects. Differences in dosage were stated as the reason, but that is not a satisfactory explanation.
2) Does not the fact that Intact I & II (gefitinib) (17, 18) and (20) were all negative studies conflict with the evidence in BR-21 study. There is the explanation based on their effects on the cell cycle that anticancer drugs and EGFR-TKIs act antagonistically when administered simultaneously.
3) Non-inferiority versus docetaxel was demonstrated in the
Interest study (gefitinib) even though the ISEL study (gefitinib) was negative. By contrast, although Japanese patients, who have a high response rate to EGFR-TKIs, were used as the study subjects of the V15-32 study (gefitinib), the docetaxel control group tended to have better survival at each time point of 10-12 months after the beginning of treatment. 4) In the SWOG S0023, which evaluated differences according to whether gefitinib was used after radiochemotherapy, survival time was significantly shorter in the gefitinib group (24) . Reason. Although considerable patient selection was involved, it was a randomized controlled trial.
5) Do the results of the Interest and BR-21 studies suggest
that the efficacy of gefitinib and erlotinib is equivalent? (21, 27) Is it legitimate to speculate and argue whether there are differences in efficacy based on the results of clinical studies with completely different study designs.
These questions suggest that the basic assumptions underlying clinical trial results of anticancer drugs can not be applied to molecularly targeted therapy.
Against this background the following are conceivable.
1) The response rates of Western people and Asian people to EGFR-TKIs are different, and the reason for the difference is a difference in EGFR mutation rate(28∼44).
2) At present it is unknown whether EGFR mutations are a predictor of the therapeutic efficacy of EGFR-TKIs or even a predictor of the therapeutic efficacy of cytotoxic anticancer drugs(26).
3) EGFR-TKIs display a potent antitumor effect in cells that possess the target, but have no effect at all on cells that do not possess it. By contrast, because cytotoxic anticancer drugs exert an antitumor effect against whole tumor mass ( Fig. 1) , the effect that they have on survival time is different from that of molecularly targeted drugs even if the response rates are equivalent according to the RECIST criteria (Fig. 2) . The concept of "long NC" does not apply to molecularly targeted drugs such as EGFR-TKIs. Actually, in the V15-32 study the response rate to gefitinib was approximately twofold compared with docetaxel(26), but non-inferiority could not be demonstrated, and survival time at each time point assessed in the gefitinib group was slightly poorer than in the docetaxel group at each time point during early phase after the beginning of treatment (Table 3 , Fig. 3, 4) . Waterfall plots are being used often recently. We can show the differences in efficacy between anticancer drugs and molecularly targeted drugs in figures (Fig.   2 ).
The basis of molecularly targeted therapy is that it should be used to treat patients who harbor the target. 
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